[{"data":1,"prerenderedAt":22},["ShallowReactive",2],{"notifications-general-fr":3,"compound-CBDP-fr":4},"En raison des vacances d'été, le laboratoire fonctionnera selon un horaire modifié du 22 juillet au 9 août 2026. Les résultats d’analyse seront disponibles 7 à 10 jours après la réception de l’échantillon. Merci de votre compréhension.",{"name":5,"shortname":6,"synonyms":6,"cas":7,"molMass":8,"pubchemLink":9,"structure":10,"important":11,"synthetic":12,"compoundClass":13,"asociationImage":16,"summarySet":17,"compoundEffectSet":21},"cannabidiphorol","CBDP","55824-13-0",342,"https:\u002F\u002Fpubchem.ncbi.nlm.nih.gov\u002Fcompound\u002F49873141","science\u002Fstructures\u002FCBDP.png",true,false,{"id":14,"description":15},"2","Cannabinoids","",[18],{"summaryText":19,"language":20},"\u003Cp>Cannabidiphorol (CBDP) is one of the more understudied and overlooked cannabinoids currently in existence. It’s a heptyl homolog of cannabidiol (CBD), non-intoxicating, and won’t induce a euphoric high, unlike tetrahydrocannabinol (THC) and tetrahydrocannabiphorol (THCP). However, CBDP might be similar to CBD in activating certain receptor types and influencing brain chemicals to improve mood and sleep. These benefits mean CBDP might potentially be a psychoactive compound (without mental or cognitive impairment). Researchers theorize heptyl cannabinoids with seven-link chains have greater affinity at various receptor sites, as evidenced with THCP, which is approximately 30-times more efficient at binding to cannabinoid 1 (CB1) receptors than THC. A \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F34577048\u002F\" target=\"_blank\">recent study\u003C\u002Fa> published September 14, 2021, shows combining CBDP, CBD, and drugs inhibiting enzymes that break down endocannabinoids produces anti-proliferative effects.  \u003C\u002Fp>",null,[],1785925845007]